Statin use in outpatient period after primary percutaneous coronary intervention for acute coronary syndrome

Secondary prevention of cardiovascular events is very important in reducing morbidity and mortality in patients after ACS. Studies have shown the effectiveness of pharmacotherapy in improving patient prognosis. According to many published studies, up to 40-75% of patients after ACS do not receive adequate pharmacotherapy in the outpatient period, which is increasing risk of mortality and re-hospitalization. The objective of the study is to analyze statin use in outpatient period after primary percutaneous coronary intervention (PCI) due to acute coronary syndrome (ACS). In a cross-sectional observational study 28 patients were examined after primary PCI for ACS. The average duration of the study was 7 months. Study patients completed face-to-face and telephone survey to obtain data of statin use and serum LDLH levels. All study patients received recommendations for statin use at the moment of discharge from a hospital. At the moment of the survey only 21 patients (75%) had correct statin therapy. One patient used statin 2 times a week. Three patients used inappropriately low statin dose. One patient had double medication. LDLH target level <1.4 mmol/L was reached in 2 patients of 7. Statin use for secondary prevention of cardiovascular events in outpatient period after ACS is not sufficient in the study patients, which was reflected in failure to achieve target LDLH values. The most common treatment errors are underuse of medications, incorrect medication dose and double medication.